ISSN: 0974-276X
Clarissa Desjardins
Canada
Research Article
Global Proteomics: Pharmacodynamic Decision Making via Geometric Interpretations of Proteomic Analyses
Author(s): Paul Kearney, Nathan L. Currier, Daniel Chelsky, Clarissa Desjardins, Patrice Hugo, Joanna Hunter, Eustache Paramithiotis, Marc Riviere, Olivier Maes, Howard M. Cherkow and Hyman M. Schipper
Paul Kearney, Nathan L. Currier, Daniel Chelsky, Clarissa Desjardins, Patrice Hugo, Joanna Hunter, Eustache Paramithiotis, Marc Riviere, Olivier Maes, Howard M. Cherkow and Hyman M. Schipper
Disease and drugs can modulate the concentrations of hundreds of proteins in the blood which can be accurately measured using contemporary proteomic methods. Nevertheless, it is common practice to reduce the plurality of disease and drug effects by a few proteins for the pragmatic purposes of immunoassay development. The vast majority of putative biomarkers discovered by this reductionist approach never reach the clinic for two reasons: the prohibitive time and cost of assay development and the acute risk of a reduced protein panel failing when validated on a broader cross-section of the population. Global Proteomics is an alternate methodology where all blood proteins modulated by disease or drug are used to resolve pharmacodynamic questions without the time, cost, and risk of developing an immunoassay. The Global Proteomic approach was applied to an Alzheimer study .. View More»
DOI:
10.4172/jpb.1000040